The Food and Drug Administration recently approved gene therapy to treat sickle cell disease among children ages 2 and older, which a Nashville doctor described as a medical milestone.
Click in for more news from The Hill{beacon} Healthcare Health Care The Big Story Democrats weaponize Big Beautiful Bill ...
WKRN Nashville on MSN
FDA approves gene therapy for young children with sickle cell disease
In a major medical breakthrough, the FDA has approved a gene therapy for children with sickle cell disease.
HealthDay on MSN
FDA expands use of first sickle cell disease gene therapy for children as young as 2 years
The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent ...
Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.
Cece Calhoun ’21, medical director of Yale’s Sickle Cell Program, reflects on the challenges of building teams and structures ...
The 500,000-square-foot facility, designed as a global gene therapy manufacturing complex, spans a full city block along ...
The National Institute on Aging of the National Institutes of Health has awarded a five-year grant initially worth $8.37 ...
On July 1, 2026, Vertex Pharmaceuticals announced that the FDA approved an expanded indication for CASGEVY (exagamglogene autotemcel) to ...
Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market.
Fast, local cryopreservation is a consistent bottleneck for autologous cell therapy developers, even in major cell and gene therapy hubs.
New Vericheck ddPCR™ Kits Combine Highly Specific and Highly Sensitive DNA Detection and Quantification with the QX700™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results